Knobby22
Mmmmmm 2nd breakfast
- Joined
- 13 October 2004
- Posts
- 9,680
- Reactions
- 6,530
Interesting. Nasal spray application in Australia dropped. I can't see it making much money here in any case but why so hard when it is sold overseas? A good decision but SP down to 89c.
"We have withdrawn the application for inclusion of the SPL7013 Nasal Spray in the Australian Register of Therapeutic Goods (ARTG), which would have allowed marketing in Australia. Thedecision comes after a more than three-year application and TGA review process that hasconsumed significant internal resources, which will now be directed towards our other strategic priorities and high-priority DEP® platform projects.
“We have not made this decision lightly and have thoroughly explored alternative options based on the current status of the application and ongoing engagement with the regulator. After careful consideration and external regulatory legal advice, the Board and management have determined that withdrawing the application at this time to focus on our strategic priorities is in the best interest of Starpharma and our shareholders. “The SPL7013 Nasal Spray is registered in over 35 countries, including the UK and Europe, and we will continue to market the product in these regions. We have ongoing marketing campaigns in these areas aimed at boosting revenue, aligning with our third strategic objective of long-term sustainability.
"We have withdrawn the application for inclusion of the SPL7013 Nasal Spray in the Australian Register of Therapeutic Goods (ARTG), which would have allowed marketing in Australia. Thedecision comes after a more than three-year application and TGA review process that hasconsumed significant internal resources, which will now be directed towards our other strategic priorities and high-priority DEP® platform projects.
“We have not made this decision lightly and have thoroughly explored alternative options based on the current status of the application and ongoing engagement with the regulator. After careful consideration and external regulatory legal advice, the Board and management have determined that withdrawing the application at this time to focus on our strategic priorities is in the best interest of Starpharma and our shareholders. “The SPL7013 Nasal Spray is registered in over 35 countries, including the UK and Europe, and we will continue to market the product in these regions. We have ongoing marketing campaigns in these areas aimed at boosting revenue, aligning with our third strategic objective of long-term sustainability.
